1 Introduction
==============

DNA methylation is the best studied epigenetic aberration underlying oncogenesis. Besides genetic mutations, hypermethylation and hypomethylation of genes (increased and decreased methylation in a disease relative to a normal state) is an alternative mechanism that is capable of altering the normal transcriptional state and driving a wide range of diseases. Prior studies have focused on the analysis of DNA methylation data, for example in breast cancer or to identify differentially methylated regions for specific DNA methylation platforms ([@bty156-B9]; [@bty156-B10]). A recent pancancer study of DNA-methylation ([@bty156-B6]) revealed 10 pancancer clusters reflecting new similarities across malignantly transformed tissues. Furthermore, several computational tools have been developed incorporating state-of-the-art statistical techniques for the analysis of DNA methylation data ([@bty156-B1]).

In [@bty156-B5], we introduced MethylMix: an algorithm that integrates DNA methylation from normal and disease samples and matched gene expression data to identify likely DNA methylation driven genes in diseases. The main output of MethylMix is a novel metric called 'Differential Methylation value' or 'DM-value' defined as the difference of an abnormal methylation state (Hypermethylated or hypomethylated) from the normal methylation state. These methylation states are computed using a beta mixture model on the beta-values.

Here, we present MethylMix 2.0, the updated version of MethylMix that features functions for downloading and preprocessing DNA methylation and gene expression datasets from all cancer sites in The Cancer Genome Atlas (TCGA). We also demonstrate an application of MethylMix for cancer subtyping and show how to use the DM-values for clustering using the R package ConsensusClusterPlus ([@bty156-B11]).

2 Algorithm
===========

MethylMix 2.0 identifies DNA methylation driven genes by modeling DNA methylation data in cancer versus normal and looking for homogeneous subpopulations. In addition, matched gene expression data can be used to identify transcriptionally predictive DNA methylation events by requiring a negative correlation between methylation and gene expression of a particular gene. Therefore, MethylMix 2.0 requires DNA methylation from normal and disease samples and matched disease gene expression data. In MethylMix 2.0, we have automated the construction of the methylation and gene expression datasets from TCGA via a three-step algorithm: Step 1: Automated Downloading from TCGA: DNA methylation datasets and Gene expression Datasets are downloaded automatically from TCGA by supplying the TCGA cancer code. We have provided the functionality to study any of the 33 TCGA cancer sites that are currently available.Step 2: Automated preprocessing: The preprocessing steps include eliminating samples and genes with too many missing values, imputing remaining missing values and batch correction across technical batches.Step 3: Clustering of the CpG probes: The methylation data produced by the Illumina 450k methylation array consists of multiple CpG probes for each gene. Since the probes are highly correlated, we clustered them prior to learning a mixture model. We used a complete linkage hierarchical clustering algorithm for all probes of a single gene to cluster the probes into CpG clusters. Then we cut off the hierarchical tree at a Pearson correlation threshold of 0.7.The outputs of these functions are numeric matrices (***METcancer***, ***METnormal*** and ***GEcancer***) with genes in rows and samples in columns to be used as inputs in MethylMix for further analysis.

3 Functions and examples
========================

MethylMix 2.0 was implemented in the statistical language R and is provided as an R package, and is also available on bioconductor. MethylMix 2.0 was designed to identify transcriptionally predictive DNA methylation events using a beta mixture modeling approach ([@bty156-B5]). MethylMix 2.0 requires three datasets as inputs: cancer DNA methylation data (***METcancer***), normal DNA methylation data (***METnormal***) and matched disease gene expression data (***GEcancer***). These datasets can be downloaded as follows using the appropriate TCGA cancer codes (example OV for Ovarian Cancer):

`> library(MethylMix)` `> cancerSite` `<- “OV”``>` `targetDirectory` `<- paste0(getwd(), “/”)``> METdirectories` `<- Download_DNAmethylation(cancerSite, targetDirectory, TRUE)``> GEdirectories` `<- Download_GeneExpression(cancer Site, targetDirectory, TRUE)`

For DNA-methylation and Gene Expression, we used the Broad Institute Firehose tool ([@bty156-B4]), which includes several preprocessing steps such as removing problematic rows, removing redundant columns, reordering the columns and sorting the data by gene name. MethylMix's contribution to the preprocessing consists of eliminating samples and genes with too many missing values, imputing remaining missing values and performing batch correction across technical batches within each cancer type.

We used an adjustable missing value threshold for removing samples or genes with too many missing values. The default threshold is a conservative one where genes with more than 20% of missing data are removed and we applied a K-Nearest Neighbors approach with K = 15 to estimate the remaining missing values, as proposed in [@bty156-B8]. Since TCGA data was generated in sample batches, we implemented batch correction to remove any systematic differences between technical batches. To this end, we used the ComBat algorithm introduced by [@bty156-B7] that removes known batch effects by implementing empirical Bayes methods for adjusting for additive, multiplicative and exponential batch effects. These adjustments methods are robust to small sample sizes. Since DNA methylation data generally do not follow a normal distribution, we used the nonparametric version of ComBat to correct the DNA methylation data.

`> METProcessedData` `<- Preprocess_DNAmethylation (cancerSite, METdirectories)``> GEProcessedData` `<- Preprocess_GeneExpression (cancerSite, GEdirectories)`

The last step for preprocessing the methylation data is to assign each probe to a gene based on their closest transcription start site. Then for each gene, we cluster all its CpG sites using hierarchical clustering with complete linkage and the Pearson correlation as distance metric. If data for normal samples is provided, some probes might be removed in the normal samples or in the cancer samples due to a high number of missing values. In this case, only overlapping probes between cancer and normal samples are retained because MethylMix provides an analysis of the differential methylation.

`> res` `<- ClusterProbes(METProcessedData[[1]], METProcessedData[[2]])`

Probes with SNPs are removed since SNPs within the probe binding sequence prevent methylation of that CpG site. Additionally, MethylMix 2.0 provides a function ***getData*** that wraps the functions for downloading and preprocessing DNA methylation and gene expression data, as well as for clustering CpG probes.

`> cancerSite` `<- “OV”``> targetDirectory` `<- paste0(getwd(), “/”)``> GetData(cancerSite, targetDirectory)`

Next, it should be noted that all these functions are prepared to run in parallel if the user registers a parallel structure, otherwise they run sequentially.

Finally, the user can also use MethylMix with data that is not from TCGA. To use custom data, the user has to provide DNA methylation beta-values of a cancer cohort and optionally normal DNA methylation data and matched gene expression data in the form of a data.matrix object in R with the rows corresponding to the genes and the columns to the sample. In addition, the user can provide batch information in the case where multiple technical batches were used to generate the data. MethylMix can be applied on all Illumina DNA methylation arrays, including the newly released Epic platform and any microarray that outputs beta values. Similarly, sequencing-based methylation data can be modeled, if the data is formatted in proportions, but, as mixture modeling is computationally demanding, MethylMix will require proportionally more time to finish as the number of CpG sites is bigger.

4 Applications
==============

The main output of MethylMix are the 'DM-values', which reflect the homogeneous subpopulations of samples with a particular methylation state. An application of the DM-values is to identify DNA methylation subtypes. For instance in lung squamous cell carcinoma ([Fig. 1](#bty156-F1){ref-type="fig"}), a DNA hypomethylated subtype featuring genetic inactivation of NSD1 was identified ([@bty156-B3]; [@bty156-B151]). DNA methylation subtypes were discovered by applying consensus clustering (a widely-used algorithm for clustering patients based on molecular data) to the 'DM-values' matrix output of MethylMix. Patients are thereby clustered into robust and homogenous groups (putative subtypes) based on their abnormal methylation profiles. Consensus clustering was performed using the ConsensusClusterPlus R package (Version 1.36.0) ([@bty156-B11]), with 1000 rounds of k-means clustering and a maximum of k = 10 clusters. Selection of the best number of clusters was based on the visual inspection of ConsensusClusterPlus output plots.

![Subtyping of lung squamous cell carcinoma patients based on MethylMix2.0 analysis. This heatmap illustrates 'DM values' for 638 MethylMix genes (rows) in 503 LUSC patient primary tumors (columns). Patients are ordered by DNA methylation subtype, indicated in the horizontal sidebar. DNA methylation subtypes represent patient groups with distinct DNA methylation profiles that are homogenous within subtypes. The NSD1-inactivated subtype is highlighted in red, with other (NSD1 proficient) subtypes indicated in grey. Horizontal sidebars indicate the category of each patient with regard to key etiological variables including NSD1 mutations (white space reflects patients without NSD1 mutation data), smoking status, sex, pathological stage and smoking status. MethylMix genes (rows) are ordered by hierarchical clustering](bty156f1){#bty156-F1}

Exploration of somatic mutation and copy number alteration data revealed that one patient cluster (indicated by the red sidebar) represents a DNA hypomethylated subtype that is enriched for inactivating genetic mutations and deletions in the NSD1, encoding a histone lysine methyltransferase. Indeed, six of ten patients with NSD1 mutations in LUSC were within the NSD1 subtype (Chi-squared *P* = 0.005). This mirrors the phenotype of a similar hypomethylated, NSD1-inactivated subtype that was recently described in head and neck squamous cell carcinoma ([@bty156-B2]).

`> source(“https://bioconductor.org/biocLite.R”`) `> biocLite(“ConsensusClusterPlus”)``> library(“ConsensusClusterPlus”)``> MethylMixResults <- MethylMix(METcancer, GEcancer, METnormal)``> DMvalues <- MethylMixResults$MethylationStates``> cons_cluster <- ConsensusClusterPlus(d = DMvalues, maxK = 10, reps = 1000, pItem = 0.8, distance=’euclidean’, clusterAlg=“km”)`

5 Conclusion
============

MethylMix 2.0 is an R package that provides automated functionalities that improve upon the original MethylMix algorithm. In MethylMix 2.0 we have implemented an automated process to download and preprocess these datasets directly from TCGA in a few lines of code. In addition, we have demonstrated a key application of MethylMix, identifying robust subgroups. In summary, MethylMix 2.0 offers a tool that facilitates the systematic analysis of methylation-driven genes in pan-cancer studies from TCGA.
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